Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin launches Ganirelix Acetate Injection in US
Details : Ganirelix Acetate-Generic is a synthetic decapeptide used to prevent premature LH surges during controlled ovarian hyperstimulation.
Product Name : Ganirelix Acetate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment
Details : Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Product Name : Antagonä-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 07, 2023
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable